Compounds > clofibrate

clofibrate and vulm 1457

clofibrate has been researched along with vulm 1457 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adameová, A; Faberová, V; Kuzelová, M; Svec, P2
Bednáriková, M; Drímal, D; Drímal, J; Fáberová, V; Schmidtová, L1
Adameová, A; Faberová, V; Kuzelová, M; Ravingerová, T; Svec, P1
Hózová, R; Mátyás, S; Sadlonová, I; Svec, P; Syneková, M; Tazká, D; Vojtassáková, E1

Other Studies

5 other study(ies) available for clofibrate and vulm 1457

ArticleYear
The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats.
    Die Pharmazie, 2005, Volume: 60, Issue:9

    Topics: Animals; Blood Glucose; Cholesterol; Cholesterol, Dietary; Clofibrate; Diabetes Mellitus, Experimental; Dietary Fats; Enzyme Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Liver; Rats; Rats, Wistar; Sterol O-Acyltransferase; Triglycerides

2005
The ACAT inhibitor VULM1457 significantly reduced production and secretion of adrenomedullin (AM) and down-regulated AM receptors on human hepatoblastic cells.
    General physiology and biophysics, 2005, Volume: 24, Issue:4

    Topics: Adrenomedullin; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Clofibrate; Dose-Response Relationship, Drug; Down-Regulation; Humans; Peptides; Receptors, Adrenomedullin; Receptors, Peptide; Sterol O-Acyltransferase

2005
Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats.
    Die Pharmazie, 2006, Volume: 61, Issue:9

    Topics: Animals; Arrhythmias, Cardiac; Blood Glucose; Cholesterol; Cholesterol, Dietary; Clofibrate; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Reperfusion Injury; Simvastatin; Sterol O-Acyltransferase

2006
The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo.
    European journal of pharmacology, 2007, Dec-08, Volume: 576, Issue:1-3

    Topics: Animals; Anti-Arrhythmia Agents; Cholesterol, Dietary; Clofibrate; Diabetes Mellitus, Experimental; Hypercholesterolemia; Hypolipidemic Agents; Male; Myocardial Infarction; Rats; Rats, Wistar; Reperfusion Injury; Sterol O-Acyltransferase

2007
Effect of VULM 1457, an ACAT inhibitor, on serum lipid levels and on real time red blood cell flow in diabetic and non-diabetic hamsters fed high cholesterol-lipid diet.
    General physiology and biophysics, 2007, Volume: 26, Issue:4

    Topics: Animals; Blood Flow Velocity; Blood Glucose; Cholesterol; Cholesterol, Dietary; Clofibrate; Cricetinae; Diabetes Mellitus; Diet; Dietary Fats; Erythrocytes; Lipids; Male; Sterol O-Acyltransferase; Triglycerides

2007